Comparison of intravitreal ranibizumab and bevacizumab treatment for retinopathy of prematurity

Detalhes bibliográficos
Autor(a) principal: Erol,Muhammet Kazim
Data de Publicação: 2015
Outros Autores: Coban,Deniz Turgut, Sari,Esin Sogutlu, Bilgin,Ahmet Burak, Dogan,Berna, Ozdemir,Ozdemir, Tunay,Zuhal Ozen
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Arquivos brasileiros de oftalmologia (Online)
Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-27492015000600340
Resumo: ABSTRACT Purpose: To compare the efficacy of intravitreal ranibizumab and bevacizumab treatment for type 1 retinopathy of prematurity (ROP). Methods: 36 eyes of 20 patients with type 1 ROP who received anti-vascular endothelial growth factor (anti-VEGF) intravitreal injections between August 2011 and February 2013 were retrospectively evaluated. Fifteen eyes of 8 patients received 0.25 mg ranibizumab (group 1), and 21 eyes of 12 patients received 0.625 mg bevacizumab (group 2). Eyes were examined by indirect ophthalmoscopy on the first day, third day, first week, and first month and as required after injections. Laser photocoagulation was performed in cases with progression of ROP. Results: The mean gestation time was 26.2 ± 2.7 weeks in group 1 patients and 27.1 ± 2.5 weeks in group 2 patients. No statistical difference in the time of gestation was observed between the two groups. The mean follow-up period was 20 ± 4.5 months. Laser photocoagulation was performed in 6 of 15 eyes from group 1 and 2 of 21 eyes from group 2. No eyes developed retinal detachment during the follow-up period. Conclusion: Ranibizumab and bevacizumab showed an efficacy in the treatment of type 1 ROP. The incidence of disease relapse was higher in eyes which received ranibizumab. Further randomized, controlled clinical trials are required to compare the efficacy of ranibizumab and bevacizumab.
id CBO-2_81b48505e2ce0c5806f3ef121421100a
oai_identifier_str oai:scielo:S0004-27492015000600340
network_acronym_str CBO-2
network_name_str Arquivos brasileiros de oftalmologia (Online)
repository_id_str
spelling Comparison of intravitreal ranibizumab and bevacizumab treatment for retinopathy of prematurityRetinopathy of prematurityVascular endothelial growth factor AAntibodies, monoclonalAngiogenesis inhibitorsIntravitreal injectionsABSTRACT Purpose: To compare the efficacy of intravitreal ranibizumab and bevacizumab treatment for type 1 retinopathy of prematurity (ROP). Methods: 36 eyes of 20 patients with type 1 ROP who received anti-vascular endothelial growth factor (anti-VEGF) intravitreal injections between August 2011 and February 2013 were retrospectively evaluated. Fifteen eyes of 8 patients received 0.25 mg ranibizumab (group 1), and 21 eyes of 12 patients received 0.625 mg bevacizumab (group 2). Eyes were examined by indirect ophthalmoscopy on the first day, third day, first week, and first month and as required after injections. Laser photocoagulation was performed in cases with progression of ROP. Results: The mean gestation time was 26.2 ± 2.7 weeks in group 1 patients and 27.1 ± 2.5 weeks in group 2 patients. No statistical difference in the time of gestation was observed between the two groups. The mean follow-up period was 20 ± 4.5 months. Laser photocoagulation was performed in 6 of 15 eyes from group 1 and 2 of 21 eyes from group 2. No eyes developed retinal detachment during the follow-up period. Conclusion: Ranibizumab and bevacizumab showed an efficacy in the treatment of type 1 ROP. The incidence of disease relapse was higher in eyes which received ranibizumab. Further randomized, controlled clinical trials are required to compare the efficacy of ranibizumab and bevacizumab.Conselho Brasileiro de Oftalmologia2015-12-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-27492015000600340Arquivos Brasileiros de Oftalmologia v.78 n.6 2015reponame:Arquivos brasileiros de oftalmologia (Online)instname:Conselho Brasileiro de Oftalmologia (CBO)instacron:CBO10.5935/0004-2749.20150090info:eu-repo/semantics/openAccessErol,Muhammet KazimCoban,Deniz TurgutSari,Esin SogutluBilgin,Ahmet BurakDogan,BernaOzdemir,OzdemirTunay,Zuhal Ozeneng2015-12-09T00:00:00Zoai:scielo:S0004-27492015000600340Revistahttp://aboonline.org.br/https://old.scielo.br/oai/scielo-oai.phpaboonline@cbo.com.br||abo@cbo.com.br1678-29250004-2749opendoar:2015-12-09T00:00Arquivos brasileiros de oftalmologia (Online) - Conselho Brasileiro de Oftalmologia (CBO)false
dc.title.none.fl_str_mv Comparison of intravitreal ranibizumab and bevacizumab treatment for retinopathy of prematurity
title Comparison of intravitreal ranibizumab and bevacizumab treatment for retinopathy of prematurity
spellingShingle Comparison of intravitreal ranibizumab and bevacizumab treatment for retinopathy of prematurity
Erol,Muhammet Kazim
Retinopathy of prematurity
Vascular endothelial growth factor A
Antibodies, monoclonal
Angiogenesis inhibitors
Intravitreal injections
title_short Comparison of intravitreal ranibizumab and bevacizumab treatment for retinopathy of prematurity
title_full Comparison of intravitreal ranibizumab and bevacizumab treatment for retinopathy of prematurity
title_fullStr Comparison of intravitreal ranibizumab and bevacizumab treatment for retinopathy of prematurity
title_full_unstemmed Comparison of intravitreal ranibizumab and bevacizumab treatment for retinopathy of prematurity
title_sort Comparison of intravitreal ranibizumab and bevacizumab treatment for retinopathy of prematurity
author Erol,Muhammet Kazim
author_facet Erol,Muhammet Kazim
Coban,Deniz Turgut
Sari,Esin Sogutlu
Bilgin,Ahmet Burak
Dogan,Berna
Ozdemir,Ozdemir
Tunay,Zuhal Ozen
author_role author
author2 Coban,Deniz Turgut
Sari,Esin Sogutlu
Bilgin,Ahmet Burak
Dogan,Berna
Ozdemir,Ozdemir
Tunay,Zuhal Ozen
author2_role author
author
author
author
author
author
dc.contributor.author.fl_str_mv Erol,Muhammet Kazim
Coban,Deniz Turgut
Sari,Esin Sogutlu
Bilgin,Ahmet Burak
Dogan,Berna
Ozdemir,Ozdemir
Tunay,Zuhal Ozen
dc.subject.por.fl_str_mv Retinopathy of prematurity
Vascular endothelial growth factor A
Antibodies, monoclonal
Angiogenesis inhibitors
Intravitreal injections
topic Retinopathy of prematurity
Vascular endothelial growth factor A
Antibodies, monoclonal
Angiogenesis inhibitors
Intravitreal injections
description ABSTRACT Purpose: To compare the efficacy of intravitreal ranibizumab and bevacizumab treatment for type 1 retinopathy of prematurity (ROP). Methods: 36 eyes of 20 patients with type 1 ROP who received anti-vascular endothelial growth factor (anti-VEGF) intravitreal injections between August 2011 and February 2013 were retrospectively evaluated. Fifteen eyes of 8 patients received 0.25 mg ranibizumab (group 1), and 21 eyes of 12 patients received 0.625 mg bevacizumab (group 2). Eyes were examined by indirect ophthalmoscopy on the first day, third day, first week, and first month and as required after injections. Laser photocoagulation was performed in cases with progression of ROP. Results: The mean gestation time was 26.2 ± 2.7 weeks in group 1 patients and 27.1 ± 2.5 weeks in group 2 patients. No statistical difference in the time of gestation was observed between the two groups. The mean follow-up period was 20 ± 4.5 months. Laser photocoagulation was performed in 6 of 15 eyes from group 1 and 2 of 21 eyes from group 2. No eyes developed retinal detachment during the follow-up period. Conclusion: Ranibizumab and bevacizumab showed an efficacy in the treatment of type 1 ROP. The incidence of disease relapse was higher in eyes which received ranibizumab. Further randomized, controlled clinical trials are required to compare the efficacy of ranibizumab and bevacizumab.
publishDate 2015
dc.date.none.fl_str_mv 2015-12-01
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-27492015000600340
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-27492015000600340
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 10.5935/0004-2749.20150090
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv text/html
dc.publisher.none.fl_str_mv Conselho Brasileiro de Oftalmologia
publisher.none.fl_str_mv Conselho Brasileiro de Oftalmologia
dc.source.none.fl_str_mv Arquivos Brasileiros de Oftalmologia v.78 n.6 2015
reponame:Arquivos brasileiros de oftalmologia (Online)
instname:Conselho Brasileiro de Oftalmologia (CBO)
instacron:CBO
instname_str Conselho Brasileiro de Oftalmologia (CBO)
instacron_str CBO
institution CBO
reponame_str Arquivos brasileiros de oftalmologia (Online)
collection Arquivos brasileiros de oftalmologia (Online)
repository.name.fl_str_mv Arquivos brasileiros de oftalmologia (Online) - Conselho Brasileiro de Oftalmologia (CBO)
repository.mail.fl_str_mv aboonline@cbo.com.br||abo@cbo.com.br
_version_ 1754209028642177024